Who
George C. Clark
VP, Chief Accounting Officer
Company insider
Files Form 4 as: VP, Chief Accounting Officer, Biohaven; VP, Chief Accounting Officer, Biohaven Pharmaceutical Holding Co.
In numbers
- Trades disclosed
- 59
- Buys
- 1
- Sells
- 3
- Bought
- $145K
- Sold
- $1.9M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 23 Nov 2021
- Last trade
- 27 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $11K1,117 at $9.93 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $11K1,117 at $9.93 | filing |
| 17 Nov 2025filed 18 Nov 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $145K17,000 at $8.52 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —2,500 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $43K1,117 at $38.64 | filing |
| 2 Jan 2024filed 4 Jan 2024 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,500 at $0.00 | filing |
| 2 Nov 2023filed 6 Nov 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 3 Oct 2022filed 3 Oct 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code D | —3,000 | filing |
| 3 Oct 2022filed 3 Oct 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code D | —1,000 | filing |
| 3 Oct 2022filed 3 Oct 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 3 Oct 2022filed 3 Oct 2022 | Biohaven Pharmaceutical Holding Cooption or derivative | SEC FORM 4 Code D | —1,750 | filing |
News
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeBHVN · insidermonkey.com · 23 Oct 2026Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpBHVN · rttnews.com · 22 Oct 2026Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026
0 headlines in the last 90 days name George C. Clark; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.